Eli Lilly to apply for approval of anti-obesity drug retatrutide in 2027
The Eli Lilly logo appears at the company's office in San Diego, California, on November 21, 2025. Mike Blake |…
Biotechnology and pharmaceuticals
UnitedHealth Group (UNH) earnings in the second quarter of 2026
UnitedHealth Group on Thursday posted second-quarter earnings that beat estimates and raised its full-year profit outlook as the company better…
The biotechnology recovery is not a farce. These 3 stocks could lead the next bullish leg
The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies.…
Employers Are Not Expanding Coverage of GLP-1 Anti-Obesity Drugs: Survey
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
AstraZeneca trial failure raises bigger questions about its portfolio
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…
Abivax receives $920 million in cash to prepare for US launch: CEO
AbivaxThe latest round of funding allows the biotech to move toward launching its intestinal disease drug in the United States…
AstraZeneca shares fall 9% after heart drug trial falls short of target
Actions of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to…
FDA allows Philip Morris-owned Zyn to be marketed as less harmful cigarettes
The Food and Drug Administration on Tuesday authorized Philip MorrisZyn's proprietary Zyn nicotine pouches will be marketed as less harmful…
Jim Cramer Says This Former Covid Market Favorite May Finally Be Invested Again
modern Expanding the portfolio beyond infectious diseases is giving investors a new reason to own stocks after years of uncertainty…
Walmart and CVS step in to help seniors
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…